The Global Anti-vascular Endothelial Growth Factor Therapeutics Market was valued at USD 13 billion in 2024 and is estimated to grow at a CAGR of 6.1% to reach USD 23.3 billion by 2034, driven by the increasing awareness of eye diseases and the demand for effective treatments. The aging population and the rising prevalence of conditions like age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion are major contributors to this expansion. These diseases often lead to abnormal blood vessel growth, which VEGF inhibitors effectively target. As a result, these therapeutics play a vital role in improving vision outcomes and controlling disease progression.
The growing incidence of diabetic retinopathy, which affects approximately one-third of diabetes patients globally, has further fueled the demand for VEGF inhibitors. With the aging population and increasing rates of diabetes, the need for these therapies is expected to rise significantly. Anti-VEGF therapeutics work by inhibiting VEGF, a protein that encourages the growth of new blood vessels, particularly in conditions with abnormal angiogenesis. These treatments are used in managing diseases like AMD and diabetic retinopathy, helping to prevent further deterioration and manage symptoms associated with excessive blood vessel formation.
The market is segmented based on products such as Eylea, Lucentis, Beovu, Vabysmo, and others. Eylea holds the largest share of the market, accounting for 51.8% in 2024, owing to its proven efficacy and strong clinical performance in treating conditions like AMD and diabetic macular edema (DME). The drug’s longer dosing regimen reduces the need for frequent injections, which enhances its appeal to both patients and healthcare providers. Eylea’s safety and effectiveness in various trials have cemented its status as a preferred treatment option, strengthening its dominance in the market.
In addition to the prevalence of age-related macular degeneration (AMD), which dominates the market with a 46.5% share in 2024, diabetic retinopathy and retinal vein occlusion are significant drivers of the anti-VEGF therapeutics market. As the global population ages, the incidence of AMD continues to rise, particularly among older adults. The progressive nature of the disease, which leads to the loss of central vision, makes it one of the primary targets for anti-VEGF therapies. These therapies help slow the progression of AMD and improve vision outcomes, making them a critical treatment for those affected by the condition.
United States Anti-Vascular Endothelial Growth Factor (VEGF) Therapeutics Market generated USD 6.7 billion in 2024, driven by its rapidly aging population, which increases the demand for treatments related to eye diseases such as AMD. The country’s advanced healthcare infrastructure and high accessibility to cutting-edge treatments contribute to the widespread adoption of anti-VEGF therapies. The robust healthcare reimbursement system in the U.S. further facilitates patients' access to these advanced therapies, driving market growth.
The major companies in the market include Bayer, Alcon, Amgen, Biogen, Novartis, and Regeneron Pharmaceuticals. These players have been expanding their portfolios and focusing on research and development to offer more targeted and efficient treatments. Partnerships with healthcare providers, investment in clinical trials, and efforts to improve the accessibility of treatments are key strategies to strengthen their market presence and foster growth in the anti-VEGF therapeutics space.
This product will be delivered within 2-4 business days.
The growing incidence of diabetic retinopathy, which affects approximately one-third of diabetes patients globally, has further fueled the demand for VEGF inhibitors. With the aging population and increasing rates of diabetes, the need for these therapies is expected to rise significantly. Anti-VEGF therapeutics work by inhibiting VEGF, a protein that encourages the growth of new blood vessels, particularly in conditions with abnormal angiogenesis. These treatments are used in managing diseases like AMD and diabetic retinopathy, helping to prevent further deterioration and manage symptoms associated with excessive blood vessel formation.
The market is segmented based on products such as Eylea, Lucentis, Beovu, Vabysmo, and others. Eylea holds the largest share of the market, accounting for 51.8% in 2024, owing to its proven efficacy and strong clinical performance in treating conditions like AMD and diabetic macular edema (DME). The drug’s longer dosing regimen reduces the need for frequent injections, which enhances its appeal to both patients and healthcare providers. Eylea’s safety and effectiveness in various trials have cemented its status as a preferred treatment option, strengthening its dominance in the market.
In addition to the prevalence of age-related macular degeneration (AMD), which dominates the market with a 46.5% share in 2024, diabetic retinopathy and retinal vein occlusion are significant drivers of the anti-VEGF therapeutics market. As the global population ages, the incidence of AMD continues to rise, particularly among older adults. The progressive nature of the disease, which leads to the loss of central vision, makes it one of the primary targets for anti-VEGF therapies. These therapies help slow the progression of AMD and improve vision outcomes, making them a critical treatment for those affected by the condition.
United States Anti-Vascular Endothelial Growth Factor (VEGF) Therapeutics Market generated USD 6.7 billion in 2024, driven by its rapidly aging population, which increases the demand for treatments related to eye diseases such as AMD. The country’s advanced healthcare infrastructure and high accessibility to cutting-edge treatments contribute to the widespread adoption of anti-VEGF therapies. The robust healthcare reimbursement system in the U.S. further facilitates patients' access to these advanced therapies, driving market growth.
The major companies in the market include Bayer, Alcon, Amgen, Biogen, Novartis, and Regeneron Pharmaceuticals. These players have been expanding their portfolios and focusing on research and development to offer more targeted and efficient treatments. Partnerships with healthcare providers, investment in clinical trials, and efforts to improve the accessibility of treatments are key strategies to strengthen their market presence and foster growth in the anti-VEGF therapeutics space.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2024
Chapter 5 Market Estimates and Forecast, by Product, 2021-2034 ($ Mn)
Chapter 6 Market Estimates and Forecast, by Application, 2021-2034 ($ Mn)
Chapter 7 Market Estimates and Forecast, by Region, 2021-2034 ($ Mn)
Chapter 8 Company Profiles
Companies Mentioned
The companies featured in this anti-vascular endothelial growth factor therapeutics (VEGF) market report include:- Alcon
- Amgen
- Bausch Health Companies
- Bayer
- Biogen
- Bristol-Myers Squibb
- Coherus BioSciences
- Eli Lilly and Company
- F. Hoffmann-La Roche
- Hoya Corporation
- Novartis
- Pfizer
- Regeneron Pharmaceuticals
- Sanofi
- Viatris
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 130 |
| Published | April 2025 |
| Forecast Period | 2024 - 2034 |
| Estimated Market Value ( USD | $ 13 Billion |
| Forecasted Market Value ( USD | $ 23.3 Billion |
| Compound Annual Growth Rate | 6.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
